P2RY12 and neoplasm: In a preclinical study of pancreatic cancer demonstrated that the combination of ticagrelor with gemcitabine exhibited synergistic effects which led to significantly reduced tumor growth compared to minimal effects observed with either gemcitabine or ticagrelor as monotherapies135. Nonetheless, P2Y12 therapy (e.g. Clopidogrel), like other anti-aggregation treatments, is associated with an increased risk of bleeding.